Concomitant Statin Use and Survival in Patients With Cancer on Immune Checkpoint Inhibitors: A Meta-Analysis
Yonghe Liao,
Yuxuan Lin,
Xinqi Ye
и другие.
JCO Oncology Practice,
Год журнала:
2025,
Номер
unknown
Опубликована: Янв. 7, 2025
PURPOSE
The
prognostic
significance
of
concomitant
statin
use
in
cancer
treatment
with
immune
checkpoint
inhibitors
(ICIs)
remains
a
subject
ongoing
investigation.
This
study
aims
to
clarify
the
value
this
patient
population
and
provide
robust,
evidence-based
foundation
guide
therapeutic
decisions.
METHODS
A
systematic
search
strategy
was
used
across
multitude
digital
archives
exhaustively
identify
all
relevant
academic
literature
published
up
until
June
20,
2024.
Studies
English
that
reported
hazard
ratios
(HRs)
for
overall
survival
(OS)
and/or
progression-free
(PFS),
along
corresponding
95%
CIs,
were
considered
eligible
inclusion.
Meta-analyses
conducted
calculate
combined
HRs
CIs.
RESULTS
total
25
studies,
involving
46,154
patients
cancer,
included
meta-analysis.
pooled
results
indicated
linked
better
OS
(HR,
0.80
[95%
CI,
0.71
0.92])
PFS
0.69
under
ICI
therapy.
Sensitivity
analyses
further
validated
consistency
robustness
results.
CONCLUSION
On
basis
available
clinical
evidence,
is
an
improved
prognosis
oncology
on
ICI-based
These
observations
underscore
potential
as
important
adjunctive
therapy
paradigm
ICI-treated
thereby
establishing
their
key
consideration
management
strategies.
Further
randomized
controlled
trials
are
imperative
validate
effect
within
realm
Язык: Английский
Lipids in the tumor microenvironment: immune modulation and metastasis
Frontiers in Oncology,
Год журнала:
2024,
Номер
14
Опубликована: Сен. 26, 2024
Tumor
cells
can
undergo
metabolic
adaptations
that
support
their
growth,
invasion,
and
metastasis,
such
as
reprogramming
lipid
metabolism
to
meet
energy
demands
promote
survival
in
harsh
microenvironmental
conditions,
including
hypoxia
acidification.
Metabolic
rewiring,
especially
alterations
metabolism,
not
only
fuel
tumor
progression
but
also
influence
immune
cell
behavior
within
the
microenvironment
(TME),
leading
immunosuppression
evasion.
These
processes,
turn,
may
contribute
metastatic
spread
of
cancer.
The
diverse
profiles
subsets,
driven
by
TME
tumor-derived
signals,
complex
landscape
tumors,
affecting
activation,
differentiation,
effector
functions.
Understanding
targeting
heterogeneity
among
subsets
will
be
crucial
for
developing
effective
cancer
immunotherapies
overcome
evasion
mechanisms
enhance
antitumor
immunity.
Язык: Английский
Enhancing the Efficacy of CAR-T Cell Production Using BX795 and Rosuvastatin in a Serum-Free Medium
International Journal of Molecular Sciences,
Год журнала:
2025,
Номер
26(7), С. 2988 - 2988
Опубликована: Март 25, 2025
Chimeric
Antigen
Receptor
T-cell
(CAR-T)
therapy
has
emerged
as
a
transformative
approach
for
cancer
treatment,
demonstrating
remarkable
success
in
patients
with
relapsed
and
refractory
hematological
malignancies.
However,
challenges
persist
optimizing
CAR-T
cell
production
improving
therapeutic
outcomes.
One
of
the
major
hurdles
is
efficiency
retroviral
or
lentiviral
transduction
during
manufacturing.
Additionally,
heterogeneity
populations
isolated
from
can
impact
effectiveness
persistence
vivo.
This
article
explores
novel
strategy
to
address
these
by
focusing
on
serum-free
medium
additive
optimization.
We
propose
unique
that
incorporates
culturing
T
cells
Nutri-T
medium,
along
24
h
exposure
combined
low
concentrations
BX795
rosuvastatin,
enhance
efficacy
functionality
cells.
The
results
presented
here
provide
promising
insights
into
potential
this
produce
more
effective
immunotherapy,
ultimately
advancing
field
benefiting
worldwide.
Язык: Английский
Statin Therapy for NAFLD: Molecular underpinnings of Myopathic Consequences and Treatment Strategies
Aspects of Molecular Medicine,
Год журнала:
2025,
Номер
unknown, С. 100091 - 100091
Опубликована: Май 1, 2025
Язык: Английский
Evaluation of immune checkpoint inhibitor-associated hepatotoxic adverse events: A pharmacovigilance analysis based on the FAERS database
International Journal of Immunopathology and Pharmacology,
Год журнала:
2025,
Номер
39
Опубликована: Март 1, 2025
Objective:
To
investigate
the
comprehensive
landscape
of
hepatotoxic
adverse
events
(AEs)
associated
with
immune
checkpoint
inhibitors
(ICIs),
a
special
focus
on
evaluating
potential
risk
lethal
AEs.
Introduction:
The
widespread
adoption
ICIs
has
markedly
improved
prognosis
for
patients
advanced
cancer.
However,
this
therapeutic
advance
is
accompanied
by
immune-related
(irAEs),
especially
AEs,
which
particularly
affect
pre-existing
liver
diseases
or
hepatobiliary
cancers.
Methods:
Reports
in
FAERS
database
from
Q1
2014
to
Q3
2024
were
collected.
characteristics
ICI-related
AEs
summarized.
Disproportionality
analysis
was
conducted
calculate
reported
odds
ratios
assessing
signals
Additionally,
logistic
regression
employed
evaluate
patient-related
factors
contributing
an
increased
these
Results:
Hepatotoxic
yearly
and
occurred
primarily
tumors.
CTLA-4
exhibited
highest
incidence
In
contrast,
PD-1
had
shortest
median
time
AE
onset.
Abnormal
hepatic
function
common
AE,
whereas
Stauffer’s
syndrome
identified
as
rare
AE.
notably
elevated
combination
immunotherapy
concurrent
use
specific
drugs.
Despite
variations
safety
profiles
different
ICI
regimens,
differences
did
not
significantly
influence
fatal
hepatotoxicity.
Furthermore,
older
men
who
experienced
other
found
be
at
higher
developing
Conclusion:
vary
widely,
necessitating
individualized
drug
selection
based
patient-specific
factors.
Язык: Английский
Mechanism of atorvastatin in treating hepatocellular carcinoma: a study based on network pharmacology, molecular docking, and bioinformatics analysis
Naunyn-Schmiedeberg s Archives of Pharmacology,
Год журнала:
2024,
Номер
unknown
Опубликована: Ноя. 28, 2024
Язык: Английский
Effect of Statin Lipophilicity on the Proliferation of Hepatocellular Carcinoma Cells
Biology,
Год журнала:
2024,
Номер
13(6), С. 455 - 455
Опубликована: Июнь 19, 2024
The
HMG-CoA
reductase
inhibitors,
statins,
are
drugs
used
globally
for
lowering
the
level
of
cholesterol
in
blood.
Different
clinical
studies
statins
cancer
patients
have
indicated
a
decrease
mortality,
particularly
using
lipophilic
compared
to
those
on
hydrophilic
statins.
In
this
paper,
we
selected
two
structurally
different
(simvastatin
and
pravastatin)
with
lipophilicities
investigated
their
effects
proliferation
apoptosis
hepatocellular
carcinoma
cells.
Lipophilic
simvastatin
highly
influences
cell
growth
survival
time-
concentration-dependent
manner,
while
pravastatin,
due
its
structure
limited
cellular
uptake,
showed
minimal
cytotoxic
effects.
Язык: Английский